New antibody drug takes aim at Hard-to-Treat cancers

NCT ID NCT07607054

Recruiting now Disease control Sponsor: Shanghai EpimAb Biotherapeutics Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests a new drug called EMB-15 in about 50 adults with advanced solid tumors that have not responded to standard treatments. EMB-15 is a bi-specific antibody designed to help the immune system attack cancer cells. The main goals are to check safety, find the right dose, and see if the drug shows any signs of shrinking tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: EMB-15 (a bi-specific antibody targeting ALPP/ALPG and CD3)
What this could lead to: If successful, this could lead to a new treatment option for people with advanced solid tumors that have not responded to standard therapies.
What could go wrong: This is a very early Phase 1 trial with only 50 participants, so safety and effectiveness are not yet known. The drug may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LOCALLY ADVANCED OR METASTATIC SOLID TUMORS

Contacts and locations

Locations

Sixth Affiliated Hospital of Sun Yat-sen University
RECRUITING

Guangzhou, Guangdong, 510655, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.